These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22289258)

  • 21. Pharmacogenetics of oral anticoagulants: a basis for dose individualization.
    Stehle S; Kirchheiner J; Lazar A; Fuhr U
    Clin Pharmacokinet; 2008; 47(9):565-94. PubMed ID: 18698879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: proposal for a new dosing regimen.
    El Din MS; Amin DG; Ragab SB; Ashour EE; Mohamed MH; Mohamed AM
    Int J Lab Hematol; 2012 Oct; 34(5):517-24. PubMed ID: 22533669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacogenetic impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate.
    Palacio L; Falla D; Tobon I; Mejia F; Lewis JE; Martinez AF; Arcos-Burgos M; Camargo M
    Clin Appl Thromb Hemost; 2010 Feb; 16(1):83-90. PubMed ID: 19567378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cytochrome P4502C9(CYP2C9) gene polymorphism and safety of therapy with warfarin].
    Mikheeva IuA; Kropacheva ES; Ignat'ev IV; Bulytova IuM; Ramenskaia GV; Sychev DA; Dobrovol'skiĭ AB; Panchenko EP
    Kardiologiia; 2008; 48(3):52-7. PubMed ID: 18429757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes.
    Veenstra DL; Blough DK; Higashi MK; Farin FM; Srinouanprachan S; Rieder MJ; Rettie AE
    Clin Pharmacol Ther; 2005 May; 77(5):353-64. PubMed ID: 15900281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort.
    Moridani M; Fu L; Selby R; Yun F; Sukovic T; Wong B; Cole DE
    Clin Biochem; 2006 Jun; 39(6):606-12. PubMed ID: 16630605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
    Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
    J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel single nucleotide polymorphism in CYP2C9 is associated with changes in warfarin clearance and CYP2C9 expression levels in African Americans.
    Hernandez W; Aquino-Michaels K; Drozda K; Patel S; Jeong Y; Takahashi H; Cavallari LH; Perera MA
    Transl Res; 2015 Jun; 165(6):651-7. PubMed ID: 25499099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factor VII R353Q genetic polymorphism is associated with altered warfarin sensitivity among CYP2C9 *1/*1 carriers.
    Mlynarsky L; Bejarano-Achache I; Muszkat M; Caraco Y
    Eur J Clin Pharmacol; 2012 May; 68(5):617-27. PubMed ID: 22071881
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation.
    Santos PC; Dinardo CL; Schettert IT; Soares RA; Kawabata-Yoshihara L; Bensenor IM; Krieger JE; Lotufo PA; Pereira AC
    Eur J Clin Pharmacol; 2013 Apr; 69(4):789-97. PubMed ID: 22990331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.
    Takahashi H; Kashima T; Nomizo Y; Muramoto N; Shimizu T; Nasu K; Kubota T; Kimura S; Echizen H
    Clin Pharmacol Ther; 1998 May; 63(5):519-28. PubMed ID: 9630825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy].
    Liu Y; Zhong SL; Tan HH; Yang M; Fei HW; Yu XY; Lin SG
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):929-35. PubMed ID: 22321278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
    Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA
    Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.
    Sconce EA; Khan TI; Wynne HA; Avery P; Monkhouse L; King BP; Wood P; Kesteven P; Daly AK; Kamali F
    Blood; 2005 Oct; 106(7):2329-33. PubMed ID: 15947090
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin.
    Ma C; Zhang Y; Xu Q; Yang J; Zhang Y; Gao L; Xu B; Wang H; Li Y; Lu C; Yin T
    Int J Hematol; 2012 Dec; 96(6):719-28. PubMed ID: 23104259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose.
    Zhang X; Li L; Ding X; Kaminsky LS
    Drug Metab Dispos; 2011 Aug; 39(8):1433-9. PubMed ID: 21562147
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism.
    Liu Y; Jeong H; Takahashi H; Drozda K; Patel SR; Shapiro NL; Nutescu EA; Cavallari LH
    Clin Pharmacol Ther; 2012 Apr; 91(4):660-5. PubMed ID: 22378156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association Between the Lower Extremity Deep Venous Thrombosis, the Warfarin Maintenance Dose, and CYP2C9*3, CYP2D6*10, and CYP3A5*3 Genetic Polymorphisms: A Case-Control Study.
    Ju S; Gao Y; Cao X; Zhang XF; Yan CC; Liu FT
    Genet Test Mol Biomarkers; 2017 Sep; 21(9):539-546. PubMed ID: 28872889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors.
    Lane S; Al-Zubiedi S; Hatch E; Matthews I; Jorgensen AL; Deloukas P; Daly AK; Park BK; Aarons L; Ogungbenro K; Kamali F; Hughes D; Pirmohamed M
    Br J Clin Pharmacol; 2012 Jan; 73(1):66-76. PubMed ID: 21692828
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variability in CYP2C9 allele frequency: a pilot study of its predicted impact on warfarin response among healthy South and North Indians.
    Nahar R; Deb R; Saxena R; Puri RD; Verma IC
    Pharmacol Rep; 2013; 65(1):187-94. PubMed ID: 23563037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.